title: Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase.
abstract: The authors aimed to study the impact of adherence to imatinib during initial 6 mo on the cytogenetic response in pediatric chronic myeloid leukemia - chronic phase (CML CP). The hospital records of pediatric CML patients (age ≤18 y) from 2009 through 2012, were analyzed retrospectively for the drug adherence and cytogenetic response (CyR) at 6 mo. Forty eight children were analyzed, with the median age of 13 y (range 5-18) and slight male preponderance (M:F- 1.18:1). Sokal scores were low, intermediate and high in 14 (29.3 %), 26 (54.1 %), 8 (16.6 %) children respectively. Only a little more than half of the children were adherent (58 %). At the end of 6 mo, complete cytogenetic response (CCyR) was achieved by 78.5 % of adherent children as compared to 5 % of non-adherent children. Majority (80 %) of the non-adherent children had only a partial cytogenetic response (PCyR). Therefore, it is concluded that most of the adherent children had optimal cytogenetic response at the end of 6 mo and majority of those in the non-adherent group did not attain it.
authors: Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, 500082, India.
authors: Ranga Raman
authors: RR
authors: Ganta
authors: Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, 500082, India.
authors: Srividya
authors: S
authors: Nasaka
authors: Department of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, 500082, India. drssgundeti@gmail.com.
authors: Sadashivudu
authors: S
authors: Gundeti
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000178:diet therapy*; D015466:Leukemia, Myeloid, Chronic-Phase; D008297:Male; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate
keywords: CML CP; Cytogenetic response at 6 mo; Imatinib adherence